Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy
to treat cervical cancer. People in this study have cervical cancer that has spread to other
parts of the body (metastatic) or has come back after being treated (recurrent).
Participants in this trial will be randomly assigned to one of two groups. One group will be
treated with tisotumab vedotin. Participants in the other group will get one of four
different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, or irinotecan).
Participants and their doctors will know which group they are in. Participants in the
chemotherapy group will decide with their study doctor which drug they will take.